Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion ...

Data from the study revealed that patients in both groups achieved the same scores on the MADRS scale, which was an average 12.5-point decrease in depression symptoms. MADRS is a metric showing ...

The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single dose of BPL-003 (mebufotenin benzoate) in patients with ...

The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score to Week ...

Patients were treated with escalating doses of escitalopram up to 50 mg for up to 32 weeks until they achieved remission (Montgomery–Asberg Depression Rating Scale [MADRS] ≤8) or failed to ...

A clinical response was defined as a 50% or greater improvement in depression symptoms on the widely-used Montgomery-Åsberg Depression Rating Scale (MADRS), which was seen in 47% of the biomarker ...

The primary outcome is the change from baseline on the Montgomery-Åsberg Depression Rating Scale, or MADRS, score. ALTO-300, an oral, small molecule designed to act as a melatonin agonist and 5 ...

The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week ...